Love Pharma (CSE:LUV) Inc. said it has changed its name from Glenbriar Technologies Inc and completed the arm's-length acquisition of British Columbia-based Kick Pharmaceuticals.
The international sexual health, wellness, and psychedelics company issued 183,067,857 common shares, at $0.10 per share, to the shareholders of Kick. In concurrent transactions, also at $0.10 per share, it issued 20,000,000 shares to the shareholders of 1288339 BC Ltd and 3,000,000 to Callitas Health, Inc. under certain product license agreements.
As part of the transaction, the company said Zach Stadnyk has joined its board of directors and has assumed the role of president and CEO, with former Glenbriar CEO Doug Taylor remaining on the board.
READ: Love Pharma appoints Joshua Maurice as chief operating officer
The company, which also announced a two-for-one share consolidation, said its shares will commence trading under the symbol LUV on the CSE on September 30, 2021.
Love Pharma holds exclusive licenses to produce market, package, sell, and distribute patent-protected therapeutic and pharmaceutical products throughout Europe, the United Kingdom, and North America.
Love anticipates increasing value for shareholders through further mergers and acquisitions that complement its strong portfolio of intellectual property.
Contact the author at stephen.gunnion@proactiveinvestors.com